298 related articles for article (PubMed ID: 33970738)
41. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Bøttcher TM; Cold S; Jensen AB
Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
[TBL] [Abstract][Full Text] [Related]
42. [A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Kudo S; Makino T; Umetsu R; Tanaka T
Gan To Kagaku Ryoho; 2021 Apr; 48(4):519-521. PubMed ID: 33976037
[TBL] [Abstract][Full Text] [Related]
43. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
Front Oncol; 2021; 11():810023. PubMed ID: 35223458
[TBL] [Abstract][Full Text] [Related]
44. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
[TBL] [Abstract][Full Text] [Related]
45. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
46. Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib.
Modi ND; Abuhelwa AY; Badaoui S; Shaw E; Shankaran K; McKinnon RA; Rowland A; Sorich MJ; Hopkins AM
Breast; 2021 Aug; 58():57-62. PubMed ID: 33906086
[TBL] [Abstract][Full Text] [Related]
47. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
48. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
[TBL] [Abstract][Full Text] [Related]
50. Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
Watson NW; Wander SA; Shatzel JJ; Al-Samkari H
Cancer; 2022 Sep; 128(17):3224-3232. PubMed ID: 35767226
[TBL] [Abstract][Full Text] [Related]
51. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
52. Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.
Takada S; Maeda H; Umehara K; Kuwahara S; Yamamoto M; Tomioka N; Takahashi M; Watanabe K; Hashishita H
Asian Pac J Cancer Prev; 2023 Jun; 24(6):1955-1962. PubMed ID: 37378924
[TBL] [Abstract][Full Text] [Related]
53. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
54. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
55. CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Huang HW; Huang LS; Xu QN; Wang HB; Li XY; Lin JZ
Medicine (Baltimore); 2019 Jan; 98(1):e13909. PubMed ID: 30608416
[TBL] [Abstract][Full Text] [Related]
56. Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study.
Mycock K; Zhan L; Taylor-Stokes G; Milligan G; Mitra D
Curr Oncol; 2021 Jan; 28(1):678-688. PubMed ID: 33498797
[TBL] [Abstract][Full Text] [Related]
57. Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Gerratana L; Kocherginsky M; Davis AA; D'Amico P; Reduzzi C; Puglisi F; Cristofanilli M
Oncologist; 2024 Feb; 29(2):123-131. PubMed ID: 37935631
[TBL] [Abstract][Full Text] [Related]
58. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
59. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
